NCT03825523Completed
Immediate ART in Subjects With Opportunistic Diseases
Impact of the Timing of Antiretroviral Therapy Initiation (Immediate Versus Early) on the Mortality Rate of HIV/AIDS Patients Hospitalized With an Opportunistic Disease
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
The aim of this study is to compare the clinical response and mortality rate due to opportunistic disease in HIV-infected individuals who start immediate versus conventional antiretroviral therapy (ART). Immediate ART (iART) is defined as starting antiretroviral therapy within the first 48 hours after hospitalization. Conventional ART (cART) is defined as starting antiretroviral therapy once the opportunistic infection is under control at the discretion of the infectious disease specialist.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 114 (actual)
- First submitted
- 18 Jan 2019
- Start date
- 29 Jan 2018
- Primary completion date
- 5 Aug 2025
- Lead sponsor
- Gustavo Reyes-Teran
- Diseases
- HIV
- NCT number
- NCT03825523
What you commit to
- Study type: Interventional
- Participants enrolled: 114
- From 29 Jan 2018 to the primary completion date, 5 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Admitted exclusively for treatment of neurosyphilis without any other active opportunistic infection.
Other
- Diagnosis or clinical symptoms suggestive of cryptococcal meningitis, tuberculous meningitis, or meningitis of any other cause.
- Pregnant women.
Who the study is looking for
- HIV infection documented by ELISA or rapid test.
- Age 18 years or older.
- Hospitalized at the emergency department, intensive care unit, or clinical pulmonology ward of the National Institute of Respiratory Diseases (INER) with clinical criteria of an opportunistic infection or AIDS-related malignancy.
- Candidate to initiate first ART regimen or presenting with first- or second-line ART failure.
- ART-naïve or with ART discontinuation for at least 3 months prior to enrollment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centro de Investigacion en Enfermedades Infecciosas Coordinator of this site? Confirm its status | México | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.